Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Eugene I. Novosad"'
Autor:
B. K. Sorensen, Kennan C. Marsh, Eugene I. Novosad, T. J. Opgenorth, T. W. Von Geldern, Jinshyun R. Wu-Wong, William J. Chiou, Douglas B. Dixon, Jae Hwan-Soo, A. S. Tasker, Kester Jeffrey A, Steven A. Boyd, M. Winn, Lisa M. Hernández, Robert A. Mantei, Radhika Bal
Publikováno v:
Journal of Medicinal Chemistry. 39:1039-1048
We have discovered a novel class of endothelin (ET) receptor antagonists through pharmacophore analysis of the existing non-peptide ET antagonists. On the basis of this analysis, we determined that a pyrrolidine ring might replace the indian ring in
Autor:
Daniel J. Kerkman, Steven A. Buckner, Saul H. Rosenberg, Jae Hwan-Soo, Martin Winn, Hohn DeBernardis, Terry J. Opgenorth, John K. Pratt, Kazumi Shiosaki, Eugene I. Novosad, Ken Spina
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 4:169-172
A series of 5-membered ring heterocyclic analogs of A-81988 were synthesized in order to determine their activity as angiotensin II antagonists. The activity of these compounds in a rabbit aorta in vitro assay ranged from pA2 values of
Autor:
Stephen Condon, Jang Y. Lee, Bryan K. Sorensen, Thomas M. Zydowsky, Boyd Steven A, Daniel J. Kerkman, Steven A. Buckner, Robert J. Altenbach, Terry J. Opgenorth, Arthur A. Hancock, John F. DeBernardis, Eugene I. Novosad, Martin Winn, Fatima Z. Basha, Andrew Tasker, Biswanath De, Kazumi Shiosaki, Robert A. Mantei
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 4:173-176
Fused ring heterocyclic analogs of A-81080 (pA2= 9.9) were synthesized and their activities in the rabbit aorta in vitro assay were measued. The best compounds (pA2 = 8.6) in series 1 had R1 = Et, R2 = H, W = X = Z = C-H, and Y = C-OMe or C-COOH. In
Autor:
Eugene I. Novosad, Barbara J. Divish, Neal S. Burres, Ivan Milicic, Terry J. Opgenorth, David M. Pollock
Publikováno v:
European Journal of Pharmacology. 231:459-464
Experiments were conducted to characterize the nature of a phosphoramidon-sensitive endothelin-converting enzyme in vivo by evaluating the pressor response to a bolus intravenous (i.v.) injection of endothelin family peptides following administration
Autor:
T. J. Opgenorth, T. W. Von Geldern, H.-S. Jae, Kennan C. Marsh, Steven A. Boyd, Jinshyun R. Wu-Wong, Eugene I. Novosad, B. K. Sorensen, William J. Chiou, Lisa M. Hernández, M. Winn, Douglas B. Dixon, Robert A. Mantei, Kester Jeffrey A, A. S. Tasker, Radhika Bal
Publikováno v:
ChemInform. 27
Autor:
Terry J. Opgenorth, Eugene I. Novosad
Publikováno v:
European Journal of Pharmacology. 191:351-357
Endothelin-1 (ET-1) is reported to be the most powerful constrictor of blood vessels known. Atrial natriuretic factor is a potent relaxor of contracted vessels. This study examined the potential interaction between these vasoactive peptides on rabbit
Publikováno v:
Life Sciences. 47:2027-2033
This study evaluated the effects of rat ANP(5–28) infusion into the blood-perfused dog gracilis muscle at concentrations ranging from 30 to 10,000 pg/ml. The vasculature of gracilis muscles from anesthetized beagle dogs was isolated and pump-perfus
Autor:
Kennan C. Marsh, Terry J. Opgenorth, Brian D. Dayton, J. Ruth Wu-Wong, Thomas W. von Geldern, Martin Winn, Andrew L. Adler, Jerry L. Wessale, Eugene I. Novosad, Jae Hwan-Soo, Samuel V. Calzadilla
Publikováno v:
Clinical science (London, England : 1979). 103
Endothelins (ETs), 21-amino-acid peptides involved in the pathogenesis of various diseases, bind to ETA and ETB receptors to initiate their effects. Based on the same core structure, we have developed four small-molecule ET receptor antagonists, ABT-
Autor:
Jerry L. Wessale, William J. Chiou, Kennan C. Marsh, Bruce G. Szczepankiewicz, Thomas W. von Geldern, Eugene I. Novosad, Lisa M. Hernández, Jinshyun R. Wu-Wong, Gang Liu, Samuel V. Calzadilla, Douglas B. Dixon, Andrew L. Adler, Brian D. Dayton, Terry J. Opgenorth
Publikováno v:
European journal of pharmacology. 366(2-3)
Endothelins, 21-amino acid peptides involved in the pathogenesis of various diseases, bind to endothelin ETA and ETB receptors to initiate their effects. Here, we characterize the pharmacology of A-216546 ([2S-(2,2-dimethylpentyl)-4S-(7-methoxy-1,3-b